特発性肺線維症（IPF）の世界市場、2024～2028年

特発性肺線維症（IPF）市場は2023～2028年に14億7,320万米ドル、予測期間中のCAGRは6.78％で成長すると予測されます。

当レポートでは、特発性肺線維症（IPF）市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、呼吸器疾患の有病率の増加、高齢者人口の増加、喫煙者数の増加が牽引しています。

本調査では、今後数年間の特発性肺線維症（IPF）市場成長を牽引する主要要因の1つとして、IPFに対する医薬品パイプラインの増加を挙げています。また、IPF治療のための新薬の市場開拓やIPFの新しいパターンの出現は、市場の大きな需要につながります。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム
• 市場の特徴
• バリューチェーン分析

第3章 市場規模の評価

• 市場の定義
• 市場セグメント分析
• 市場規模 2023年
• 市場の展望 2023～2028年

第4章 市場規模実績

• 特発性肺線維症（IPF）の世界市場 2018～2022年
• 投与経路別セグメント分析 2018～2022年
• 薬剤クラス別セグメント分析 2018～2022年
• 地域別セグメント分析 2018～2022年
• 国別セグメント分析 2018～2022年

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション：投与経路別

• 市場セグメンテーション
• 比較：投与経路別
• 経口：市場規模と予測 2023～2028年
• 非経口：市場規模と予測 2023～2028年
• 市場機会：投与経路別

第7章 市場セグメンテーション：薬剤クラス別

• 市場セグメンテーション
• 比較：薬剤クラス別
• 全身性コルチコステロイド：市場規模と予測 2023～2028年
• 免疫抑制剤：市場規模と予測 2023～2028年
• チロシンキナーゼ阻害剤：市場規模と予測 2023～2028年
• 抗線維化剤：市場規模と予測 2023～2028年
• 市場機会：薬剤クラス別

第8章 顧客情勢

• 顧客情勢概要

第9章 地域別情勢

• 地域別セグメンテーション
• 比較：地域別
• 北米：市場規模と予測 2023～2028年
• 欧州：市場規模と予測 2023～2028年
• アジア：市場規模と予測 2023～2028年
• その他：市場規模と予測 2023～2028年
• 米国：市場規模と予測 2023～2028年
• 中国：市場規模と予測 2023～2028年
• 日本：市場規模と予測 2023～2028年
• ドイツ：市場規模と予測 2023～2028年
• 英国：市場規模と予測 2023～2028年
• 市場機会：地域情勢別

第10章 促進要因・課題・機会・抑制要因

• 市場促進要因
• 市場課題
• 促進要因と課題の影響
• 市場の機会・抑制要因

第11章 競合情勢

• 概要
• 競合情勢
• 混乱の状況
• 業界のリスク

第12章 競合分析

• 企業プロファイル
• 企業の市場ポジショニング
• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Co.
• Cipla Inc.
• F. Hoffmann La Roche Ltd.
• FibroGen Inc.
• Galapagos NV
• GNI Group Ltd.
• Horizon Therapeutics Plc
• Jubilant Pharmova Ltd.
• Liminal BioSciences Inc.
• MediciNova Inc.
• Novartis AG
• SHIONOGI Co. Ltd.
• United Therapeutics Corp.

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Route of Administration
• Exhibits6: Executive Summary - Chart on Market Segmentation by Drug Class
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Company Market Positioning
• Exhibits10: Parent Market
• Exhibits11: Data Table on - Parent Market
• Exhibits12: Market characteristics analysis
• Exhibits13: Value Chain Analysis
• Exhibits14: Offerings of companies included in the market definition
• Exhibits15: Market segments
• Exhibits16: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits17: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits18: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits19: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits20: Historic Market Size - Data Table on Global Idiopathic Pulmonary Fibrosis (IPF) Market 2018 - 2022 ($ million)
• Exhibits21: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
• Exhibits22: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
• Exhibits23: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• Exhibits24: Historic Market Size - Country Segment 2018 - 2022 ($ million)
• Exhibits25: Five forces analysis - Comparison between 2023 and 2028
• Exhibits26: Bargaining power of buyers - Impact of key factors 2023 and 2028
• Exhibits27: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• Exhibits28: Threat of new entrants - Impact of key factors in 2023 and 2028
• Exhibits29: Threat of substitutes - Impact of key factors in 2023 and 2028
• Exhibits30: Threat of rivalry - Impact of key factors in 2023 and 2028
• Exhibits31: Chart on Market condition - Five forces 2023 and 2028
• Exhibits32: Chart on Route of Administration - Market share 2023-2028 (%)
• Exhibits33: Data Table on Route of Administration - Market share 2023-2028 (%)
• Exhibits34: Chart on Comparison by Route of Administration
• Exhibits35: Data Table on Comparison by Route of Administration
• Exhibits36: Chart on Oral - Market size and forecast 2023-2028 ($ million)
• Exhibits37: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
• Exhibits38: Chart on Oral - Year-over-year growth 2023-2028 (%)
• Exhibits39: Data Table on Oral - Year-over-year growth 2023-2028 (%)
• Exhibits40: Chart on Parenteral - Market size and forecast 2023-2028 ($ million)
• Exhibits41: Data Table on Parenteral - Market size and forecast 2023-2028 ($ million)
• Exhibits42: Chart on Parenteral - Year-over-year growth 2023-2028 (%)
• Exhibits43: Data Table on Parenteral - Year-over-year growth 2023-2028 (%)
• Exhibits44: Market opportunity by Route of Administration ($ million)
• Exhibits45: Data Table on Market opportunity by Route of Administration ($ million)
• Exhibits46: Chart on Drug Class - Market share 2023-2028 (%)
• Exhibits47: Data Table on Drug Class - Market share 2023-2028 (%)
• Exhibits48: Chart on Comparison by Drug Class
• Exhibits49: Data Table on Comparison by Drug Class
• Exhibits50: Chart on Systemic corticosteroids - Market size and forecast 2023-2028 ($ million)
• Exhibits51: Data Table on Systemic corticosteroids - Market size and forecast 2023-2028 ($ million)
• Exhibits52: Chart on Systemic corticosteroids - Year-over-year growth 2023-2028 (%)
• Exhibits53: Data Table on Systemic corticosteroids - Year-over-year growth 2023-2028 (%)
• Exhibits54: Chart on Immunosuppressants - Market size and forecast 2023-2028 ($ million)
• Exhibits55: Data Table on Immunosuppressants - Market size and forecast 2023-2028 ($ million)
• Exhibits56: Chart on Immunosuppressants - Year-over-year growth 2023-2028 (%)
• Exhibits57: Data Table on Immunosuppressants - Year-over-year growth 2023-2028 (%)
• Exhibits58: Chart on Tyrosine kinase inhibitors - Market size and forecast 2023-2028 ($ million)
• Exhibits59: Data Table on Tyrosine kinase inhibitors - Market size and forecast 2023-2028 ($ million)
• Exhibits60: Chart on Tyrosine kinase inhibitors - Year-over-year growth 2023-2028 (%)
• Exhibits61: Data Table on Tyrosine kinase inhibitors - Year-over-year growth 2023-2028 (%)
• Exhibits62: Chart on Anti-fibrotic agents - Market size and forecast 2023-2028 ($ million)
• Exhibits63: Data Table on Anti-fibrotic agents - Market size and forecast 2023-2028 ($ million)
• Exhibits64: Chart on Anti-fibrotic agents - Year-over-year growth 2023-2028 (%)
• Exhibits65: Data Table on Anti-fibrotic agents - Year-over-year growth 2023-2028 (%)
• Exhibits66: Market opportunity by Drug Class ($ million)
• Exhibits67: Data Table on Market opportunity by Drug Class ($ million)
• Exhibits68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits69: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits70: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits71: Chart on Geographic comparison
• Exhibits72: Data Table on Geographic comparison
• Exhibits73: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits74: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits75: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibits76: Data Table on North America - Year-over-year growth 2023-2028 (%)
• Exhibits77: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits78: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits79: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits80: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits81: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits82: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits83: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits84: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits85: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits86: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits87: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits88: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits89: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibits90: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibits91: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibits92: Data Table on US - Year-over-year growth 2023-2028 (%)
• Exhibits93: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibits94: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibits95: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibits96: Data Table on China - Year-over-year growth 2023-2028 (%)
• Exhibits97: Chart on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibits98: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibits99: Chart on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits100: Data Table on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits101: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits102: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits103: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits104: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits105: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibits106: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibits107: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibits108: Data Table on UK - Year-over-year growth 2023-2028 (%)
• Exhibits109: Market opportunity By Geographical Landscape ($ million)
• Exhibits110: Data Tables on Market opportunity By Geographical Landscape ($ million)
• Exhibits111: Impact of drivers and challenges in 2023 and 2028
• Exhibits112: Overview on criticality of inputs and factors of differentiation
• Exhibits113: Overview on factors of disruption
• Exhibits114: Impact of key risks on business
• Exhibits115: Companies covered
• Exhibits116: Matrix on companies position and classification
• Exhibits117: AstraZeneca Plc - Overview
• Exhibits118: AstraZeneca Plc - Product / Service
• Exhibits119: AstraZeneca Plc - Key news
• Exhibits120: AstraZeneca Plc - Key offerings
• Exhibits121: Boehringer Ingelheim International GmbH - Overview
• Exhibits122: Boehringer Ingelheim International GmbH - Product / Service
• Exhibits123: Boehringer Ingelheim International GmbH - Key news
• Exhibits124: Boehringer Ingelheim International GmbH - Key offerings
• Exhibits125: Bristol Myers Squibb Co. - Overview
• Exhibits126: Bristol Myers Squibb Co. - Product / Service
• Exhibits127: Bristol Myers Squibb Co. - Key news
• Exhibits128: Bristol Myers Squibb Co. - Key offerings
• Exhibits129: Cipla Inc. - Overview
• Exhibits130: Cipla Inc. - Business segments
• Exhibits131: Cipla Inc. - Key news
• Exhibits132: Cipla Inc. - Key offerings
• Exhibits133: Cipla Inc. - Segment focus
• Exhibits134: F. Hoffmann La Roche Ltd. - Overview
• Exhibits135: F. Hoffmann La Roche Ltd. - Business segments
• Exhibits136: F. Hoffmann La Roche Ltd. - Key news
• Exhibits137: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibits138: F. Hoffmann La Roche Ltd. - Segment focus
• Exhibits139: FibroGen Inc. - Overview
• Exhibits140: FibroGen Inc. - Product / Service
• Exhibits141: FibroGen Inc. - Key offerings
• Exhibits142: Galapagos NV - Overview
• Exhibits143: Galapagos NV - Product / Service
• Exhibits144: Galapagos NV - Key offerings
• Exhibits145: GNI Group Ltd. - Overview
• Exhibits146: GNI Group Ltd. - Product / Service
• Exhibits147: GNI Group Ltd. - Key offerings
• Exhibits148: Horizon Therapeutics Plc - Overview
• Exhibits149: Horizon Therapeutics Plc - Product / Service
• Exhibits150: Horizon Therapeutics Plc - Key offerings
• Exhibits151: Jubilant Pharmova Ltd. - Overview
• Exhibits152: Jubilant Pharmova Ltd. - Business segments
• Exhibits153: Jubilant Pharmova Ltd. - Key news
• Exhibits154: Jubilant Pharmova Ltd. - Key offerings
• Exhibits155: Jubilant Pharmova Ltd. - Segment focus
• Exhibits156: Liminal BioSciences Inc. - Overview
• Exhibits157: Liminal BioSciences Inc. - Product / Service
• Exhibits158: Liminal BioSciences Inc. - Key offerings
• Exhibits159: MediciNova Inc. - Overview
• Exhibits160: MediciNova Inc. - Product / Service
• Exhibits161: MediciNova Inc. - Key offerings
• Exhibits162: Novartis AG - Overview
• Exhibits163: Novartis AG - Business segments
• Exhibits164: Novartis AG - Key news
• Exhibits165: Novartis AG - Key offerings
• Exhibits166: Novartis AG - Segment focus
• Exhibits167: SHIONOGI Co. Ltd. - Overview
• Exhibits168: SHIONOGI Co. Ltd. - Product / Service
• Exhibits169: SHIONOGI Co. Ltd. - Key offerings
• Exhibits170: United Therapeutics Corp. - Overview
• Exhibits171: United Therapeutics Corp. - Product / Service
• Exhibits172: United Therapeutics Corp. - Key offerings
• Exhibits173: Inclusions checklist
• Exhibits174: Exclusions checklist
• Exhibits175: Currency conversion rates for US$
• Exhibits176: Research methodology
• Exhibits177: Information sources
• Exhibits178: Data validation
• Exhibits179: Validation techniques employed for market sizing
• Exhibits180: Data synthesis
• Exhibits181: 360 degree market analysis
• Exhibits182: List of abbreviations

The idiopathic pulmonary fibrosis (IPF) market is forecasted to grow by USD 1473.2 mn during 2023-2028, accelerating at a CAGR of 6.78% during the forecast period. The report on the idiopathic pulmonary fibrosis (IPF) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of respiratory diseases, growing geriatric population, and increase in number of smokers.

Technavio's idiopathic pulmonary fibrosis (IPF) market is segmented as below:

By Route Of Administration

• Oral
• Parenteral

By Drug Class

• Systemic corticosteroids
• Immunosuppressants
• Tyrosine kinase inhibitors
• Anti-fibrotic agents

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the increase in drug pipeline for IPF as one of the prime reasons driving the idiopathic pulmonary fibrosis (IPF) market growth during the next few years. Also, development of novel drugs for treatment of IPF and emergence of new patterns of IPF will lead to sizable demand in the market.

The report on the idiopathic pulmonary fibrosis (IPF) market covers the following areas:

• Idiopathic pulmonary fibrosis (IPF) market sizing
• Idiopathic pulmonary fibrosis (IPF) market forecast
• Idiopathic pulmonary fibrosis (IPF) market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading idiopathic pulmonary fibrosis (IPF) market vendors that include Alembic Pharmaceuticals Ltd., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celix Pharma Ltd., Cipla Inc., Daewoong Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., FibroGen Inc., Galapagos NV, Galecto Inc., GNI Group Ltd., Horizon Therapeutics PLC, Intas Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Liminal BioSciences Inc., MediciNova Inc., Merck and Co. Inc., Mission Therapeutics, Novartis AG, SHIONOGI Co. Ltd., and United Therapeutics Corp.. Also, the idiopathic pulmonary fibrosis (IPF) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market By Geographical Landscape
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Market Segmentation by Drug Class
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
  • Parent Market
  • Data Table on - Parent Market
• 2.2 Market characteristics
  • Market characteristics analysis
• 2.3 Value chain analysis
  • Value Chain Analysis

3 Market Sizing

• 3.1 Market definition
  • Offerings of companies included in the market definition
• 3.2 Market segment analysis
  • Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
  • Chart on Global - Market size and forecast 2023-2028 ($ million)
  • Data Table on Global - Market size and forecast 2023-2028 ($ million)
  • Chart on Global Market: Year-over-year growth 2023-2028 (%)
  • Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global Idiopathic Pulmonary Fibrosis (IPF) Market 2018 - 2022
  • Historic Market Size - Data Table on Global Idiopathic Pulmonary Fibrosis (IPF) Market 2018 - 2022 ($ million)
• 4.2 Route of Administration segment analysis 2018 - 2022
  • Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
• 4.3 Drug Class segment analysis 2018 - 2022
  • Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
• 4.4 Geography segment analysis 2018 - 2022
  • Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.5 Country segment analysis 2018 - 2022
  • Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
  • Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
  • Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Route of Administration

• 6.1 Market segments
  • Chart on Route of Administration - Market share 2023-2028 (%)
  • Data Table on Route of Administration - Market share 2023-2028 (%)
• 6.2 Comparison by Route of Administration
  • Chart on Comparison by Route of Administration
  • Data Table on Comparison by Route of Administration
• 6.3 Oral - Market size and forecast 2023-2028
  • Chart on Oral - Market size and forecast 2023-2028 ($ million)
  • Data Table on Oral - Market size and forecast 2023-2028 ($ million)
  • Chart on Oral - Year-over-year growth 2023-2028 (%)
  • Data Table on Oral - Year-over-year growth 2023-2028 (%)
• 6.4 Parenteral - Market size and forecast 2023-2028
  • Chart on Parenteral - Market size and forecast 2023-2028 ($ million)
  • Data Table on Parenteral - Market size and forecast 2023-2028 ($ million)
  • Chart on Parenteral - Year-over-year growth 2023-2028 (%)
  • Data Table on Parenteral - Year-over-year growth 2023-2028 (%)
• 6.5 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)
  • Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Drug Class

• 7.1 Market segments
  • Chart on Drug Class - Market share 2023-2028 (%)
  • Data Table on Drug Class - Market share 2023-2028 (%)
• 7.2 Comparison by Drug Class
  • Chart on Comparison by Drug Class
  • Data Table on Comparison by Drug Class
• 7.3 Systemic corticosteroids - Market size and forecast 2023-2028
  • Chart on Systemic corticosteroids - Market size and forecast 2023-2028 ($ million)
  • Data Table on Systemic corticosteroids - Market size and forecast 2023-2028 ($ million)
  • Chart on Systemic corticosteroids - Year-over-year growth 2023-2028 (%)
  • Data Table on Systemic corticosteroids - Year-over-year growth 2023-2028 (%)
• 7.4 Immunosuppressants - Market size and forecast 2023-2028
  • Chart on Immunosuppressants - Market size and forecast 2023-2028 ($ million)
  • Data Table on Immunosuppressants - Market size and forecast 2023-2028 ($ million)
  • Chart on Immunosuppressants - Year-over-year growth 2023-2028 (%)
  • Data Table on Immunosuppressants - Year-over-year growth 2023-2028 (%)
• 7.5 Tyrosine kinase inhibitors - Market size and forecast 2023-2028
  • Chart on Tyrosine kinase inhibitors - Market size and forecast 2023-2028 ($ million)
  • Data Table on Tyrosine kinase inhibitors - Market size and forecast 2023-2028 ($ million)
  • Chart on Tyrosine kinase inhibitors - Year-over-year growth 2023-2028 (%)
  • Data Table on Tyrosine kinase inhibitors - Year-over-year growth 2023-2028 (%)
• 7.6 Anti-fibrotic agents - Market size and forecast 2023-2028
  • Chart on Anti-fibrotic agents - Market size and forecast 2023-2028 ($ million)
  • Data Table on Anti-fibrotic agents - Market size and forecast 2023-2028 ($ million)
  • Chart on Anti-fibrotic agents - Year-over-year growth 2023-2028 (%)
  • Data Table on Anti-fibrotic agents - Year-over-year growth 2023-2028 (%)
• 7.7 Market opportunity by Drug Class
  • Market opportunity by Drug Class ($ million)
  • Data Table on Market opportunity by Drug Class ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
  • Chart on Market share By Geographical Landscape 2023-2028 (%)
  • Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
  • Chart on Geographic comparison
  • Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
  • Chart on North America - Market size and forecast 2023-2028 ($ million)
  • Data Table on North America - Market size and forecast 2023-2028 ($ million)
  • Chart on North America - Year-over-year growth 2023-2028 (%)
  • Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
  • Chart on Europe - Market size and forecast 2023-2028 ($ million)
  • Data Table on Europe - Market size and forecast 2023-2028 ($ million)
  • Chart on Europe - Year-over-year growth 2023-2028 (%)
  • Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
  • Chart on Asia - Market size and forecast 2023-2028 ($ million)
  • Data Table on Asia - Market size and forecast 2023-2028 ($ million)
  • Chart on Asia - Year-over-year growth 2023-2028 (%)
  • Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
  • Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
  • Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
  • Chart on US - Market size and forecast 2023-2028 ($ million)
  • Data Table on US - Market size and forecast 2023-2028 ($ million)
  • Chart on US - Year-over-year growth 2023-2028 (%)
  • Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 China - Market size and forecast 2023-2028
  • Chart on China - Market size and forecast 2023-2028 ($ million)
  • Data Table on China - Market size and forecast 2023-2028 ($ million)
  • Chart on China - Year-over-year growth 2023-2028 (%)
  • Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.9 Japan - Market size and forecast 2023-2028
  • Chart on Japan - Market size and forecast 2023-2028 ($ million)
  • Data Table on Japan - Market size and forecast 2023-2028 ($ million)
  • Chart on Japan - Year-over-year growth 2023-2028 (%)
  • Data Table on Japan - Year-over-year growth 2023-2028 (%)
• 9.10 Germany - Market size and forecast 2023-2028
  • Chart on Germany - Market size and forecast 2023-2028 ($ million)
  • Data Table on Germany - Market size and forecast 2023-2028 ($ million)
  • Chart on Germany - Year-over-year growth 2023-2028 (%)
  • Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.11 UK - Market size and forecast 2023-2028
  • Chart on UK - Market size and forecast 2023-2028 ($ million)
  • Data Table on UK - Market size and forecast 2023-2028 ($ million)
  • Chart on UK - Year-over-year growth 2023-2028 (%)
  • Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
  • Market opportunity By Geographical Landscape ($ million)
  • Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Opportunity/Restraints

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2023 and 2028
• 10.4 Market opportunities/restraints

11 Competitive Landscape

• 11.1 Overview
• 11.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 11.3 Landscape disruption
  • Overview on factors of disruption
• 11.4 Industry risks
  • Impact of key risks on business

12 Competitive Analysis

• 12.1 Companies profiled
  • Companies covered
• 12.2 Market positioning of companies
  • Matrix on companies position and classification
• 12.3 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product / Service
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
• 12.4 Boehringer Ingelheim International GmbH
  • Boehringer Ingelheim International GmbH - Overview
  • Boehringer Ingelheim International GmbH - Product / Service
  • Boehringer Ingelheim International GmbH - Key news
  • Boehringer Ingelheim International GmbH - Key offerings
• 12.5 Bristol Myers Squibb Co.
  • Bristol Myers Squibb Co. - Overview
  • Bristol Myers Squibb Co. - Product / Service
  • Bristol Myers Squibb Co. - Key news
  • Bristol Myers Squibb Co. - Key offerings
• 12.6 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
• 12.7 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
• 12.8 FibroGen Inc.
  • FibroGen Inc. - Overview
  • FibroGen Inc. - Product / Service
  • FibroGen Inc. - Key offerings
• 12.9 Galapagos NV
  • Galapagos NV - Overview
  • Galapagos NV - Product / Service
  • Galapagos NV - Key offerings
• 12.10 GNI Group Ltd.
  • GNI Group Ltd. - Overview
  • GNI Group Ltd. - Product / Service
  • GNI Group Ltd. - Key offerings
• 12.11 Horizon Therapeutics Plc
  • Horizon Therapeutics Plc - Overview
  • Horizon Therapeutics Plc - Product / Service
  • Horizon Therapeutics Plc - Key offerings
• 12.12 Jubilant Pharmova Ltd.
  • Jubilant Pharmova Ltd. - Overview
  • Jubilant Pharmova Ltd. - Business segments
  • Jubilant Pharmova Ltd. - Key news
  • Jubilant Pharmova Ltd. - Key offerings
  • Jubilant Pharmova Ltd. - Segment focus
• 12.13 Liminal BioSciences Inc.
  • Liminal BioSciences Inc. - Overview
  • Liminal BioSciences Inc. - Product / Service
  • Liminal BioSciences Inc. - Key offerings
• 12.14 MediciNova Inc.
  • MediciNova Inc. - Overview
  • MediciNova Inc. - Product / Service
  • MediciNova Inc. - Key offerings
• 12.15 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
• 12.16 SHIONOGI Co. Ltd.
  • SHIONOGI Co. Ltd. - Overview
  • SHIONOGI Co. Ltd. - Product / Service
  • SHIONOGI Co. Ltd. - Key offerings
• 12.17 United Therapeutics Corp.
  • United Therapeutics Corp. - Overview
  • United Therapeutics Corp. - Product / Service
  • United Therapeutics Corp. - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 13.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 13.4 Research methodology
  • Research methodology
• 13.5 Data procurement
  • Information sources
• 13.6 Data validation
  • Data validation
• 13.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 13.8 Data synthesis
  • Data synthesis
• 13.9 360 degree market analysis
  • 360 degree market analysis
• 13.10 List of abbreviations
  • List of abbreviations